Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Autologous serum + balanced salt solution is a patient-derived biologic preparation used as ophthalmic drops for the treatment of persistent corneal epithelial defects (PEDs). It is produced by centrifuging the patient's own blood to isolate serum, which is then diluted with a sterile balanced salt solution (BSS), typically to a 20% concentration. The serum contains essential bioactive components, including epidermal growth factor (EGF), transforming growth factor-beta (TGF-beta), fibronectin, and vitamin A, which mimic the biochemical properties of natural tears and promote corneal epithelial cell migration, proliferation, and wound healing. Because it is autologous, it minimizes the risk of immunological rejection or preservative-induced toxicity.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on autologous serum + balanced salt solution.